July 15, 2024
Hodgkins Lymphoma Treatment Market

The Advent Of Targeted Therapies Is Anticipated To Openup The New Avenue For Hodgkins Lymphoma Treatment Market

The global Hodgkins Lymphoma Treatment Market is estimated to be valued at US$ 0.59 Bn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Hodgkin’s lymphoma is a type of cancer that affects the lymphatic system. It is also known as Hodgkin’s disease. The main symptoms include painless swelling of lymph nodes in the neck, armpits or groin area that persists for more than two to three weeks. Other symptoms may include fever, night sweats, and weight loss. Hodgkin’s lymphoma is usually treated with chemotherapy, radiation therapy or stem cell transplant based on the stage and risk factors. The common chemotherapy drugs used include doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and cyclophosphamide.

Market Dynamics:

Two major drivers of the Hodgkins lymphoma treatment market are increasing prevalence of Hodgkins lymphoma and rising research funding for novel targeted therapies. According to WHO, in 2020, around 82,000 new cases of Hodgkin lymphoma were reported globally. Due to lifestyle changes and rise in immunity related disorders, the incidence of Hodgkin lymphoma is steadily increasing worldwide. This growing prevalence rate is driving the demand for effective treatment options. Additionally, many pharmaceutical companies and academic research institutes are investing significantly towards development of novel targeted therapies with improved efficacy and less side effects for Hodgkin lymphoma. For instance, in 2020, AbbVie received FDA approval for Venclexta in combination with rituximab for relapsed or refractory Hodgkin lymphoma. This is expected to revolutionize treatment landscape and further fuel the market growth during forecast period.

Segment Analysis

The Hodgkin’s lymphoma treatment market is segmented into chemotherapy, targeted therapy, and stem cell transplantation based on the type of treatment. Among these, the chemotherapy segment currently dominates the market owing to high preference of chemotherapy drugs such as doxorubicin, bleomycin, vinblastine, and dacarbazine by doctors for treating early stages of Hodgkin’s lymphoma. These drugs are highly effective and relatively inexpensive compared to targeted therapies and stem cell transplantation procedures.

PEST Analysis

Political: The government regulations supporting cancer research and clinical trials for new treatments are enabling pharmaceutical companies to develop novel drugs for Hodgkin’s lymphoma. Various governments are also providing reimbursement coverage for cancer therapies to increase access to treatment.
Economic: There is high investment by industry players in R&D of advanced treatment options. Increasing healthcare expenditure globally has boosted the demand for high-priced therapies.
Social: Rising patient awareness regarding early diagnosis and available treatment modalities is leading to higher treatment seeking rate for Hodgkin’s lymphoma. Support groups are also helping reduce the social stigma associated with cancer.
Technological: Continuous research in oncology has led to development of targeted therapies and immune-modulating drugs with higher efficacy and lower side effects as compared to chemotherapy. Biomarker analysis is also assisting in more personalized treatment approach.

Key Takeaways

The global Hodgkins Lymphoma Treatment Market Size is expected to witness high growth at a CAGR of 11% over the forecast period of 2023 to 2030, driven by the increasing incidence of Hodgkin’s lymphoma worldwide and the launch of novel drugs. The market size is estimated to reach US$ 1.05 Bn by 2030.

Region-wise, North America currently dominates the Hodgkin’s lymphoma treatment market owing to supportive insurance policies, high healthcare expenditure, and the presence of leading pharmaceutical players. However, Asia Pacific is poised to be the fastest growing regional market over the coming years due to rising cancer burden, improving access to diagnosis and care, and growing research activities in the region.

Key players operating in the Hodgkin’s lymphoma treatment market are Bristol Myers Squibb, Johnson & Johnson, AbbVie Inc., and Merck & Co., Inc. These companies are actively focusing on developing advanced targeted therapies and expanding indications of existing treatment options to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it